Inanc, N. Et Al. 2022. Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome.. Clinical and experimental rheumatology , vol.40, no.12 , 2290-2297.

Inanc, N., Kostov, B., Priori, R., Flores-Chavez, A., Carubbi, F., Szántó, A., ... Valim, V.(2022). Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome.. Clinical and experimental rheumatology , vol.40, no.12, 2290-2297.

Inanc, GÜZİDE Et Al. "Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome.," Clinical and experimental rheumatology , vol.40, no.12, 2290-2297, 2022

Inanc, GÜZİDE N. Et Al. "Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome.." Clinical and experimental rheumatology , vol.40, no.12, pp.2290-2297, 2022

Inanc, N. Et Al. (2022) . "Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome.." Clinical and experimental rheumatology , vol.40, no.12, pp.2290-2297.

@article{article, author={GÜZİDE NEVSUN İNANÇ Et Al. }, title={Safety and efficacy of SARS-CoV-2 vaccination in 1237 patients with primary Sjögren syndrome.}, journal={Clinical and experimental rheumatology}, year=2022, pages={2290-2297} }